REFERENCES
- Gruber C J, Tschugguel W, Schneeberger C, Huber J C. Production and action of estrogens. N Engl J Med 2002; 346: 340–352, [INFOTRIEVE], [CSA]
- Mangelsdorf D J, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans R M. The nuclear receptor superfamily: The second decade. Cell 1995; 83: 835–839, [INFOTRIEVE], [CROSSREF], [CSA]
- Pettersson K, Gustafsson J A. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001; 63: 165–192, [INFOTRIEVE], [CROSSREF], [CSA]
- Jensen E V, Jacobson H I. Basic guides to the mechanism of estrogen action. Recent Progress Horm Res 1962; 18: 387–414, [CSA]
- Green S, Walter P, Kumar V, Krust A, Bornert J M, Argos P, Chambon P. Human estrogen receptor cDNA: Sequence expression and homology to v-erb-A. Nature 1986; 320: 134–139, [INFOTRIEVE], [CROSSREF], [CSA]
- Kuiper G GJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925–5930, [INFOTRIEVE], [CROSSREF], [CSA]
- Mosselman S, Polman J, Dijkema R. Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49–53, [INFOTRIEVE], [CROSSREF], [CSA]
- Weihua Z, Andersson S, Cheng G, Simpson E R, Warner M, Gustafsson J A. Update on estrogen signaling. FEBS Lett 2003; 546: 17–24, [INFOTRIEVE], [CROSSREF], [CSA]
- Lazennec G. Estrogen receptor, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 2006; 231: 151–157, [INFOTRIEVE], [CROSSREF], [CSA]
- Kumar V, Green S, Staub A, Chambon P. Localisation of the estradiol-binding and putative DNA-binding domains of the human oestrogen receptor. EMBO J 1986; 5: 2231–2236, [INFOTRIEVE], [CSA]
- Pakdel F, Le Goff, Katzenellenbogen B S. An assessment of the role of domain F and PEST sequences in estrogen receptor half-life and bioactivity. J Steroid Biochem 1993; 46: 663–672, [CROSSREF], [CSA]
- Weatherman R V, Scanlan T S. Unique protein determinants of the subtype-selective ligand response of the estrogen receptors (ERα and ERβ) at AP-1 sites. J Biol Chem 2001; 276: 3827–3832, [INFOTRIEVE], [CROSSREF], [CSA]
- Hall J M, McDonnell D P. The estrogen receptor β -isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and anti-estrogens. Endocrinology 1999; 140: 5566–5578, [INFOTRIEVE], [CROSSREF], [CSA]
- Kuiper G G, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson J A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863–870, [INFOTRIEVE], [CROSSREF], [CSA]
- Kuiper G G, Lemmen J G, Carlsson B, Corton J C, Safe S H, van der Saag P T, van der Burg B, Gustafsson J A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor. Endocrinology 1998; 139: 4252–4263, [INFOTRIEVE], [CROSSREF], [CSA]
- Cowley S, Parker M. A comparison of the transcriptional activation by ER alpha and ER beta. J Steroid Biochem Mol Biol 1999; 69: 165–175, [INFOTRIEVE], [CROSSREF], [CSA]
- Hall J M, Couse J F, Korach K S. The multifaceted mechanism of estradiol and estrogen receptor signalling. J Biol Chem 2001; 276: 36869–36872, [INFOTRIEVE], [CROSSREF], [CSA]
- Klinge C M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29: 2905–2919, [INFOTRIEVE], [CROSSREF], [CSA]
- Coser K R, Chesnes J, Hur J, Ray S, Isselbacher K J, Shioda T. Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci USA 2003; 100: 13994–13999, [INFOTRIEVE], [CROSSREF], [CSA]
- Smith C L, O'Malley B W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocrine Rev 2004; 25: 45–71, [CROSSREF], [CSA]
- Shao W, Keeton K, McDonnell D P, Brown M. Coactivator AIB1 links estrogen receptor activity and stability. Proc Natl Acad Sci USA 2004; 101: 11599–11604, [INFOTRIEVE], [CROSSREF], [CSA]
- Dobrzycka K M, Townson S M, Jiang S, Oesterrich S. Estrogen receptor corepressors, a role in human breast cancer?. Endocr Relat Cancer 2003; 10: 517–536, [INFOTRIEVE], [CROSSREF], [CSA]
- Kushner P J, Agard D A, Green G L, Scanlan T S, Shiau A K, Uht R M, Webb P. Estrogen receptor pathway to AP-1. J Steroid Biochem Mol Med 2000; 74: 311–317, [CROSSREF], [CSA]
- Jakacka M, Ito M, Weiss J, Chien P -Y, Gehm B D, Jameson J L. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem 2001; 276: 13615–13621, [INFOTRIEVE], [CSA]
- Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nature Cell Biol 2002; 4: E131–E136, [INFOTRIEVE], [CROSSREF], [CSA]
- Paech K, Webb P, Kuiper G JM, Nilsson S, Gustafsson J A, Kushner P J, Scanlan T S. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997; 277: 1508–1510, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weihua Z, Saji S, Makinen S, Cheng G, Jensen E V, Warner M, Gustafsson J A. Estrogen receptor (ER) β, a modulator of ERα in the uterus. Proc Natl Acad Sci USA 2000; 97: 5936–5941, [INFOTRIEVE], [CROSSREF], [CSA]
- An J, Ribeiro R C, Webb P, Gustafsson J A, Kushner P J, Baxter J D, Leitman D C. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci USA 1999; 96: 15161–15166, [INFOTRIEVE], [CROSSREF], [CSA]
- Weigel N L, Zhang Y. Ligand-independent activation of steroid hormone receptors. J Mol Med 1998; 76: 469–479, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270: 1491–1494, [INFOTRIEVE], [CSA]
- Ali S, Metzger D, Bornert J M, Chambon P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human estrogen receptor A/B region. EMBO J 1993; 12: 1153–1160, [INFOTRIEVE], [CSA]
- Ignar-Trowbridge D M, Nelson K G, Bidwell M C, Curtis S W, Washburn T F, McLachlan J A, Korach K S. Coupling of dual signalling pathways. Epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA 1992; 89: 4658–4662, [INFOTRIEVE], [CROSSREF], [CSA]
- Briand P, Lundholt B K, Skouv J, Lykkesfeldt A E. Growth response of breast epithelial cells to estrogen is influenced by EGF. Mol Cell Endocrinol 1999; 153: 1–9, [INFOTRIEVE], [CROSSREF], [CSA]
- Curtis S W, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse J F, Korach K S. Physiological coupling of growth factor and steroid hormone signalling pathways: Epidermal growth action involves estrogen receptor. Proc Natl Acad Sci USA 1996; 93: 12626–12630, [INFOTRIEVE], [CROSSREF], [CSA]
- Tremblay A, Tremblay G B, Labrie F, Giguere V. Ligand-independent recruitment of SRC to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 1999; 3: 513–519, [INFOTRIEVE], [CROSSREF], [CSA]
- Wade C B, Robinson S, Shapiro R A, Dorsa D M. Estrogen receptor (ERα) and ERβ exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated-associated protein kinase pathway. Endocrinology 2001; 142: 2336–2342, [INFOTRIEVE], [CROSSREF], [CSA]
- Sak K, Everaus H. Nongenomic effects of 17β -estradiol, diversity of membrane binding sites. J Steroid Biochem Mol Biol 2004; 88: 323–335, [INFOTRIEVE], [CROSSREF], [CSA]
- Marquez D C, Pietras R J. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001; 20: 5420–5430, [INFOTRIEVE], [CROSSREF], [CSA]
- Thomas P, Pang Y, Filardo E J, Dong J. Endocrinology 2005; 146: 624–632, Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells[INFOTRIEVE], [CROSSREF], [CSA]
- Maruyama S, Fujimoto N, Asano K, Ito A. Suppression by estrogen receptor beta of AP-1 mediated transactivation through estrogen receptor alpha. J Steroid Biochem Mol Biol 2001; 78: 177–184, [INFOTRIEVE], [CROSSREF], [CSA]
- Lindberg K -M, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson J A, Ohlsson C. Estrogen receptor (ER)-β reduces ERα -regulated gene transcription, supporting a “ying yang” relationship between ERα and ERβ in mice. Mol Endocrinol 2003; 17: 203–208, [INFOTRIEVE], [CROSSREF], [CSA]
- Hayashi S -I, Eguch H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yoshida N, Yamaguchi Y. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr Relat Cancer 2003; 10: 193–202, [INFOTRIEVE], [CROSSREF], [CSA]
- Strom A, Hartman J, Foster J S, Kietz S, Wimalasena J, Gustafsson J A. Estrogen receptor β inhibits 17β -estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004; 101: 1566–1571, [INFOTRIEVE], [CROSSREF], [CSA]
- Paruthiyil S, Parmar H, Kerekatte V, Cunha G R, Firestone G L, Leitman D C. Estrogen receptor ERβ inhibits human breast cancer cell proliferation and tumor formation by causing a G2cell cycle arrest. Cancer Res 2004; 64: 423–428, [INFOTRIEVE], [CROSSREF], [CSA]
- Liehr J G. Genotoxicity of the steroidal estrogens oestrone and oestradiol: Possible mechanisms of uterine and mammary cancer development. Hum Reprod Update 2001; 7: 273–281, [INFOTRIEVE], [CROSSREF], [CSA]
- Fentiman I S. Oral contraceptives, hormone replacement therapy and breast cancer. Int J Clin Pract 2002; 56: 755–759, [INFOTRIEVE], [CSA]
- Berai V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942–944, [CROSSREF], [CSA]
- Pike M C, Spicer D M, Dahmoush L, Press M F. Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol Rev 1993; 15: 17–35, [INFOTRIEVE], [CSA]
- Clemons M, Goss P. Estrogens and risk of breast cancer. N Engl J Med 2001; 344: 276–285, [INFOTRIEVE], [CROSSREF], [CSA]
- Ciamp A, Danson S, Clemons M. Hormonal risk factors for breast cancer: Identification, chemoprevention and other intervention strategies. Lancet Oncology 2002; 3: 611–619, [CROSSREF], [CSA]
- Cuzick J, Powles T, Veronesi U. Overview of the main outcomes in breast cancer prevention. Lancet 2003; 361: 296–300, [INFOTRIEVE], [CSA]
- Buzdar A U. Hormone therapy in early and advanced breast cancer. Breast J 2004; 10(Suppl 1)s19–21, [INFOTRIEVE], [CSA]
- Cauley J A, Lucas F L, Kuller L H, Stone K, Browner W, Cummings S R, Study of Osteoporotic Fractures Research Group. Elevated serum estradiol and testosterone concentration are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Int Med 1999; 130: 270–277, [PUBMED], [INFOTRIEVE], [CSA]
- The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606–616, [CSA]
- Gustafsson J A. What pharmacologists can learn from recent advances in estrogen signalling. Trends Pharmacol Sci 2003; 24: 479–485, [INFOTRIEVE], [CROSSREF], [CSA]
- Cohen S M, Ellwein L B. Cell proliferation in carcinogenesis. Science 1990; 249: 1007–1011, [PUBMED], [INFOTRIEVE], [CSA]
- Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258: 607–615, [INFOTRIEVE], [CSA]
- Dickson R B, Lippman M E. Growth factors in breast cancer. Endocrine Rev 1995; 16: 559–589, [CROSSREF], [CSA]
- Clark R B, Howell A, Potten C S, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57: 4987–4991, [CSA]
- Clark R B, Anderson E, Howell A. Steroid receptors in human breast cancer. Trends Endocrinol Metab 2004; 15: 316–323, [CROSSREF], [CSA]
- Platet N, Cathiard A M, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: A dual role in cancer proliferation and invasion. Crit Rev Oncol Haematol 2004; 51: 55–67, [CSA]
- Bardin A, Boulle N, Lazennec G, Fignon F, Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11: 537–551, [INFOTRIEVE], [CROSSREF], [CSA]
- Roger Sahla M E, Makela S, Gustafsson J A, Baldet P, Rochefort H. Decreased expression of receptor beta protein in proliferative preinvasive tumors. Cancer Res 2001; 61: 2537–2541, [CSA]
- Clark R, Liu M C, Bouker K B, Gu Z, Lee Z G, Zhu Y, Skaar T C, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke L A. Antiestrogen resistance in breast cancer and the role of estrogen receptor signalling. Oncogene 2003; 22: 7316–7339, [CROSSREF], [CSA]
- Beatson G T. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104–107, [CSA]
- Dees E C, Davidson N E. Ovarian ablation as adjuvant therapy for breast cancer. Semin Oncol 2001; 28: 322–331, [INFOTRIEVE], [CROSSREF], [CSA]
- Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996; 348: 1189–1196, [CROSSREF], [CSA]
- Osborne C K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609–1618, [INFOTRIEVE], [CROSSREF], [CSA]
- Cameron D A, Keen J C, Dixon J M, Bellamy C, Hanby A, Anderson T J, Miller W R. Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur J Cancer 2000; 36: 845–851, [INFOTRIEVE], [CROSSREF], [CSA]
- Baum M. Tamoxifen, the treatment of choice. Why look for alternatives?. Br J Cancer 1998; 78(Suppl 4)1–4, [INFOTRIEVE], [CSA]
- Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: An overview of randomized trials. Lancet 1998; 351: 1451–1467, [CROSSREF], [CSA]
- Wakeling A E. Similarities and distinctions in the mode of action of different classes of antiestrogens. Endocr Relat Cancer 2000; 7: 17–28, [INFOTRIEVE], [CROSSREF], [CSA]
- DeFriend D J, Anderson E, Bell J, Wilks D P, West C M, Mansel R E, Howell A. Effects of 4-hydroxytamoxifen and a novel pure antiestrogen (ICI 182780) on the clonegenic growth of human breast cancer cells in vitro. Br J Cancer 1994; 70: 204–211, [INFOTRIEVE], [CSA]
- Osborne C K, Coronado-Heinsohn E B, Hilsenbeck S G, McCue B L, Wakeling A E, McCelland R A, Manning D L, Nicholson R I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746–750, [INFOTRIEVE], [CSA]
- Robertson J FR, Osborne C K, Howell A, Jones S E, Mauriac L, Ellis M, Kleeberg U R, Come S, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. Cancer 2003; 98: 229–238, [INFOTRIEVE], [CROSSREF], [CSA]
- Howell A, Robertson J FR, Abram P, Lichinitser M R, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne C K. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational double-blind randomised trial. J Clin Oncol 2004; 22: 1605–1613, [INFOTRIEVE], [CROSSREF], [CSA]
- Buzdar A, Howell A. Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7: 2620–2635, [INFOTRIEVE], [CSA]
- Howell A, Dowsett M. Aromatase inhibitors versus antiestrogens. Breast Cancer Res 2004; 6: 269–274, [INFOTRIEVE], [CROSSREF], [CSA]
- The ATAC (arimidex, tamoxifen alone or in combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359: 2131–2139, [CROSSREF], [CSA]
- Buzdar A M. Data from the arimidex, tamoxifen, alone or in combination (ATAC) trial: Implications for use of aromatase inhibitors in 2003. Clin Cancer Res 2004; 10(Suppl 1)355s–361s, [INFOTRIEVE], [CROSSREF], [CSA]
- Winer E P, Hudis C, Burstein H J, Wolff A C, Pritchard K I, Ingle J N, Chlebowski R T, Gelber R, Edge S B, Gralow J, Cobleigh M A, Mamounas P, Goldstein L J, Whelan T J, Powles T J, Bryant J, Perkins C, Perotti J, Braun S, Langer A S, Browman G P, Somerfield M R. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619–629, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Duffy M J. Predictive markers in breast and other cancers. Clin Chem 2005; 51: 494–503, [INFOTRIEVE], [CROSSREF], [CSA]
- Dixon J M, Jackson J, Hills M, Renshaw L, Cameron D A, Anderson T J, Miller W R, Dowsett M. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004; 40: 2742–2747, [INFOTRIEVE], [CROSSREF], [CSA]
- Ellis M J, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller W R, Evans D B, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1 and or ErbB2-positive, estrogen receptor positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808–3816, [PUBMED], [INFOTRIEVE], [CSA]
- Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status. J Clin Oncol 2005; 23: 7512–7517, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Osborne C K, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865S–870S, [CSA]
- Jonat W. Luteinizing hormone-releasing hormone analogues, the rationale for adjuvant use in premenopausal women with early breast cancer. Br J Cancer 1998; 78(Suppl 4)5–8, [INFOTRIEVE], [CSA]
- Blamey R W, Jonat W, Kaufmann M, Bianco A R, Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 1992; 28A: 810–814, [INFOTRIEVE], [CROSSREF], [CSA]
- Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes J C, Schumacher M, Sauerbrei W, Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003; 39: 1711–1717, [INFOTRIEVE], [CROSSREF], [CSA]
- Jensen E V, Block G E, Smith S, Kyser K, DeSombre E R. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monograph 1971; 34: 55–60, [CSA]
- McGuire W L, Carbone P P, Sears M E, Escher G C. Estrogen receptors in human breast cancer: An overview. Estrogen Receptors in Human Breast Cancer, W L McGuire, P P Carbone, E P Vollner. Raven Press, New York 1975; 1–8
- Early Breast Cancer Trialists' Collaborative Group (EBCTTG). Effect of chemotherapy and hormone therapy for early breast cancer on recurrence and 15-year survival: An overview of randomised trials. Lancet 2005; 365: 1687–1717, [CROSSREF], [CSA]
- ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60–62, [CROSSREF], [CSA]
- Leonard G D, Swain S M. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96: 906–920, [INFOTRIEVE], [CSA]
- Vogel V G, Costantino J P, Wickerham D L, Cronin W M. National surgical adjuvant breast and bowel project update: Prevention trials and endocrime therapy of ductal carcinoma in situ. Clin Cancer Res 2003; 9: 495S–501S, [INFOTRIEVE], [CSA]
- Kiang D T, Frenning D H, Goldman A I, Ascensao V F, Kennedy B J. Estrogen receptors and response to chemotherapy and hormone therapy in advanced breast cancer. N Engl J Med 1978; 299: 1330–1334, [INFOTRIEVE], [CSA]
- Lippman M E, Allegra J C. Lack of estrogen receptor associated with an increased response rate to cytotoxic chemotherapy in metastatic breast cancer. Recent Results Cancer Res 1980; 71: 155–161, [INFOTRIEVE], [CSA]
- Bear H D, Anderson S, Brown A, Smith R, Mamounas E P, Fisher B, Margolese R, Theoret H, Soran A, Wickermam D L, Wolmark N. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project B-27. J Clin Oncol 2003; 21: 4165–4174, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Faneyte I F, Schrama J G, Peterse J L, Remijnse P L, Rodenhuis S, van de Vijver M J. Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome. Br J Cancer 2003; 88: 406–412, [INFOTRIEVE], [CROSSREF], [CSA]
- Ring A E, Smith I E, Ashley S, Fulford L G, Lakhani S R. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004; 91: 2012–2017, [INFOTRIEVE], [CROSSREF], [CSA]
- Ogston K N, Miller I D, Schofield A C, Spyrantis A, Pavlidou E, Sarkar T K, Hutcheon A W, Payne S, Heys S D. Can patients likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?. Breast Cancer Res Treat 2004; 86: 181–189, [INFOTRIEVE], [CROSSREF], [CSA]
- Early Breast Cancer Trialist's Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930–942, [CROSSREF], [CSA]
- Coates A S, Gelber R D, Goldhirsch A. Subsets within the chemotherapy overview. International Breast Cancer Study Group. Lancet 1998; 352: 1783–1784, [PUBMED], [INFOTRIEVE], [CSA]
- Colleoni M, Coates A, Pagani O, Goldhirsch A. Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: Still a question?. Cancer Treat Rev 1998; 24: 15–26, [INFOTRIEVE], [CSA]
- Forbes J F, Gradishar W J, Ravdin P M. Choosing between endocrine therapy and chemotherapy—or is there a role for combination therapy?. Breast Cancer Res Treat 2002; 75(Suppl 1)S37–S44, [INFOTRIEVE], [CROSSREF], [CSA]
- Fisher B, Jeong J -H, Bryant J, Anderson S, Dignam J, Fisher E R, Wolmark N. Treatment of lymph-node negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858–868, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomised trial. J Natl Cancer Inst 2002; 94: 1054–1065, [CSA]
- International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15: 1385–1394, [CSA]
- Duffy M J. Biochemical markers as prognostic indices in breast cancer. Clin Chem 1990; 36: 188–191, [INFOTRIEVE], [CSA]
- Alanko A, Heinonen E, Scheinin T M, Tolppanen E M, Vihko R. Oestrogen and progesterone receptors and disease free interval in primary breast cancer. Br J Cancer 1984; 50: 667–672, [INFOTRIEVE], [CSA]
- Barnes D M, Millis R R, Gillett C E, Ryder K, Skilton D, Fentiman I S, Rubens R D. The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: A retrospective study of 2660 patients. Endocr Rel Cancer 2004; 11: 85–96, [CROSSREF], [CSA]
- Hilsenbeck S G, Ravdin P M, de Moor C A, Chamness G C, Osborne K, Clark G M. Time dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52: 227–237, [INFOTRIEVE], [CROSSREF], [CSA]
- Gray R J. Spline-based tests in survival analysis. Biometrics 1994; 50: 640–652, [INFOTRIEVE], [CSA]
- Pichon M F, Broet P, Magdelenat H, Delarue J C, Spyratos F, Basuyau J P, Saez S, Rallet A, Courriere P, Millon R, Asselain B. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996; 73: 1545–1551, [PUBMED], [INFOTRIEVE], [CSA]
- Costa S -D, Lange S, Klinga K, Merkle E, Kaufmann M. Factors influencing the prognostic role of oestrogen and progesterone receptors in breast cancer: Results of the analysis of 670 patients with 11 years of follow-up. Eur J Cancer 2002; 38: 1329–1334, [INFOTRIEVE], [CROSSREF], [CSA]
- Mirza A N, Mirza N Q, Vlastos G, Singletary E. Prognostic factors in node-negative breast cancer. A review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10–26, [INFOTRIEVE], [CROSSREF], [CSA]
- Speirs V, Malone C, Walton D S, Kerin M J, Atkin S L. Increased expression of estrogen receptor β mRNA in tamoxifen resistant breast cancer patients. Cancer Res 1999; 59: 5421–5424, [INFOTRIEVE], [CSA]
- Mann S, Laucirica R, Carlson N, Younes P S, Ali N, Younes A, Li Y, Younes M. Estrogen receptor beta expression in invasive breast cancer. Human Pathol 2001; 32: 113–118, [CROSSREF], [CSA]
- Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson J A, Rochefort H. Estrogen receptor beta (ER-beta) but not its ERbetacx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004; 10: 5769–5776, [INFOTRIEVE], [CROSSREF], [CSA]
- Myers E, Fleming F J, Crotty T B, Kelly G, McDermott E W, O'Higgins N J, Hill A DK, Young L S. Inverse relationship between ER-β and SRC-1 predict outcome in endocrine-resistant breast cancer. Br J Cancer 2004; 91: 1687–1693, [INFOTRIEVE], [CSA]
- Hopp T A, Weiss H L, Parra I S, Cui Y, Osborne C K, Fuqua S AW. Low levels of ERβ protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004; 10: 7490–7499, [INFOTRIEVE], [CROSSREF], [CSA]
- O'Neill P A, Davies M PA, Shaaban A M, Innes H, Torevell A, Sibson D R, Foster C S. Wild-type oestrogen receptor beta (ERβ -1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers. Br J Cancer 2004; 91: 1694–1702, [INFOTRIEVE], [CSA]
- Bast R C, Jr, Ravdin P, Hayes D F, Bates S, Fritsche H, Jr, Jessup J M, Kemeny N, Locker G Y, Mennel R G, Somerfield M R. American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865–1878, [INFOTRIEVE], [CSA]
- Molina R, Barak V, van Dalen A, Duffy M J, Einarsson R, Gion M, Goike H, Lamertz R, Nap M, Soletormos G, Stieber P. Tumor markers in breast cancer: European Group on Tumor Markers (EGTM) recommendations. Tumor Biol 2005; 26: 281–293, [CROSSREF], [CSA]
- Goldhirsch A, Glick J H, Gelber R D, Coates A S, Thurlimann B, Senn H J. Panel members. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569–1583, [INFOTRIEVE], [CROSSREF], [CSA]